ACHV — Achieve Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $141.09m
- $119.57m
Annual cashflow statement for Achieve Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -33.2 | -42.4 | -29.8 | -39.8 | -54.6 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.23 | 4.47 | 5.89 | 7.42 | 9.22 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.23 | 0.099 | -0.778 | 2.41 | -4.27 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -29.4 | -37.5 | -24.5 | -29.8 | -49.5 |
| Capital Expenditures | — | — | -0.021 | — | -0.003 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | -21.6 | 6.11 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | — | — | -0.021 | -21.6 | 6.11 |
| Financing Cash Flow Items | — | 19.1 | -0.25 | -0.114 | 45.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 36.6 | 19.3 | 15.3 | 48.5 | 51.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.17 | -18.3 | -9.22 | -2.82 | 8.18 |